AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32144874
Drug: Standard adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adherence support (counselling, two-way SMS, monthly adherence clubs)
Trial: 32144874
Drug: Standard support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard support plus drug-level feedback
Trial: 32144874
Drug: Standard adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adherence support and drug-level feedback
Trial: 33938520
Drug: Antipsychotic-naive participants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic-naive participants
Trial: 33938520
Drug: Participants previously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants previously exposed to antipsychotics
Trial: 35920410
Drug: Topical 10%
RxNorm normalized name: urea topical 10% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 10% lidocaine cream
Trial: 35920410
Drug: 10% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% lidocaine cream
Trial: 33638644
Drug: Feedback on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feedback on quantity of antibiotic use (DDD, days-of-therapy)
Trial: 33242835
Drug: Durvalumab therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab therapy following chemoradiation
Trial: 36375188
Drug: Septum-based double
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Septum-based double injection (DI group)
Trial: 36375188
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection (SI group)
Trial: 36127497
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitor (SGLT2i) treatment for 12 weeks
Trial: 34931289
Drug: Intraoperative infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative infusion of dexmedetomidine 0.4 μg·kg‐1·hr‐1
Trial: 34931289
Drug: Intraoperative infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative infusion of dexmedetomidine
Trial: 32873686
Drug: TEXT4BP intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TEXT4BP intervention (text messages containing information on hypertension, diet, medication and physical activity three times a week for 3 months)
Trial: 35114409
Drug: Potential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potential treatment mechanisms (self-efficacy, motivation, treatment engagement)
Trial: 34467593
Drug: Vonafexor 400
RxNorm normalized name: Vonafexor
DrugBank: Vonafexor (DB18782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonafexor 400 mg once daily
Trial: 34467593
Drug: Vonafexor 200
RxNorm normalized name: Vonafexor
DrugBank: Vonafexor (DB18782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonafexor 200 mg twice daily
Trial: 34467593
Drug: Vonafexor/pegylated-IFN-?2a combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonafexor/pegylated-IFN-?2a combination therapy
Trial: 33837797
Drug: Radiofrequency (RF)
RxNorm normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency (RF) treatment consisting of three monthly sessions
Trial: 33837797
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor muscle training (PFMT) consisting of 12 weekly sessions
Trial: 33837797
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of RF + PFMT
Trial: 34798853
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg MPH + 10 mg escitalopram
Trial: 34798853
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + 10 mg escitalopram
Trial: 34143831
Drug: Biological larviciding
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological larviciding with Bacillus thuringiensis israelensis (full or guided intervention)
Trial: 32653604
Drug: Bupivacaine injection
RxNorm normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine injection (0.5 %, 5 mg/mL) at a dose of 4 ml for the umbilicus and 2 ml for each 5‐mm ancillary trocar site
Trial: 32653604
Drug: Bupivacaine injection
RxNorm normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine injection (0.5 %, 5 mg/mL)
Trial: 32653604
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no bupivacaine administered)
Trial: 35803290
Drug: CAS + IMD (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAS + IMD (1200 mg subcutaneous injection)
Trial: 34423033
Drug: Melatonin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (3 mg per day for 12 weeks)
Trial: 34423033
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 mg per day for 12 weeks)
Trial: 36314057
Drug: Dexamethasone 12
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 12 mg daily
Trial: 36190994
Drug: Dexamethasone 6
RxNorm normalized name: dexamethasone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 6 mg daily
Trial: 32538495
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 6 mg/kg
Trial: 34506086
Drug: Complete decongestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete decongestive therapy (CDT)
Trial: 36927419
Drug: Low-dose CT-guided
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT-guided biopsy
Trial: 32503093
Drug: Ocrelizumab (OCR)
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab (OCR) 600 mg administered over a 2-hour infusion
Trial: 32503093
Drug: Ocrelizumab (OCR)
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab (OCR) 600 mg administered over a 3.5-hour infusion (conventional)
Trial: 33106280
Drug: Transmuscular quadratus
RxNorm normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmuscular quadratus lumborum (TQL) block with ropivacaine 60 mL 0.375%
Trial: 33106280
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (saline 60 mL)
Trial: 33050920
Drug: 3D-conformal radiotherapy
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D-conformal radiotherapy with sequential boost (Arm B: whole breast 28 × 1.8 Gy, boost 8 × 2 Gy)
Trial: 37093196
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg once daily
Trial: 34781936
Drug: Telephone health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone health coaching (THC) sessions (monthly, average 30 min for 12 months)
Trial: 34922724
Drug: Tramadol (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (75 mg) + Dexketoprofen (25 mg)
Trial: 35026038
Drug: Web-based brief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based brief intervention program for recording daily alcohol consumption for 4 weeks
Trial: 33075775
Drug: Fluoride dentifrice
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride dentifrice with 5,000 µg F/g
Trial: 33075775
Drug: Fluoride dentifrice
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride dentifrice with 1,300 µg F/g
Trial: 33075775
Drug: Fluoride dentifrice
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride dentifrice with 0 µg F/g
Trial: 33075775
Drug: Fluoride dentifrice
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride dentifrice with 700 µg F/g
Trial: 32522095
Drug: Ticagrelor (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (loading dose: 180 mg, maintenance dose: 90 mg bid)
Trial: 32522095
Drug: Clopidogrel (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (loading dose: 300 mg, maintenance dose: 75 mg qd)
Trial: 34593298
Drug: Salmon calcitonin
RxNorm normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon calcitonin nasal spray
Trial: 35108610
Drug: EFV 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EFV 400 mg
Trial: 35436807
Drug: Rim arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rim arterial phase hyperenhancement and enhanced capsule
Trial: 33186308
Drug: Intercostal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercostal nerve block using 10 ml 0.35% ropivacaine (group MINB)
Trial: 34411275
Drug: Bundled care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bundled care program including povidone-iodine skin preparation, nasal decolonization, iodine-alcohol surgical prepping solution, iodophor-impregnated incise drapes, forced-air warming blankets, and negative pressure wound therapy.
Trial: 35653595
Drug: Combined bleaching
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined bleaching (desensitizing gel for 10 minutes, in-office bleaching with 35% hydrogen peroxide for 2×15 minutes, followed by at-home bleaching with 4% hydrogen peroxide for 2×30 minutes for 21 days)
Trial: 32729099
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg/bid from 48 hours before to 24 hours after the procedure with fixed maximal voltage (Group C)
Trial: 35716457
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) added to ibuprofen + paracetamol + pregabalin
Trial: 35716457
Drug: No Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No Pentoxifylline (Control) with ibuprofen + paracetamol + pregabalin
Trial: 38247384
Drug: Hydroxyurea (HU)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HU) treatment
Trial: 34013489
Drug: Weekly phone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly phone monitoring only (Control Group)
Trial: 33988155
Drug: Pethidine 50
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 50 mg intramuscular injection
Trial: 34251533
Drug: Photobiomodulation (PBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM) treatment (660 nm, 100mW, 177 J/cm2, 5 s, 0.5 J) twice a week for 30 days
Trial: 34919073
Drug: VK2+VD3 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VK2+VD3 group (received vitamin K2, vitamin D3, and calcium treatment)
Trial: 32556827
Drug: Menopausal Hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Menopausal Hormone Therapy (MHT)
Trial: 32556827
Drug: Transdermal, newer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal, newer low-dose oral therapies, and SERM therapies
Trial: 33183463
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (CT)
Trial: 32358375
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine cooperative therapy on the basis of conventional Western medicine
Trial: 35073968
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C (25 mg/kg every 6 hours for up to 96 hours)
Trial: 35073968
Drug: Placebo (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous 5% dextrose)
Trial: 32188702
Drug: ?GalCer-pulsed APCs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ?GalCer-pulsed APCs administered intravenously four times
Trial: 34913980
Drug: Oral azithromycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral azithromycin, 10 mg/kg once daily for 3 days
Trial: 33983395
Drug: Level B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level B (oxaliplatin 104 mg/m2, capecitabine 500 mg/m2)
Trial: 33983395
Drug: Level C
RxNorm normalized name: Precision Tri-Level Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level C (oxaliplatin 78 mg/m2, capecitabine 375 mg/m2)
Trial: 36297065
Drug: Wheat biscuits
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat biscuits enriched with L-arginine (ArgB)
Trial: 34097705
Drug: Mathematical model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mathematical model of heparin clearance for protamine dosing
Trial: 34097705
Drug: Fixed ratio
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed ratio of 1 mg of protamine for every 100 IU of heparin
Trial: 34030591
Drug: US-guided percutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided percutaneous catheter placement and hydrostatic pressure irrigation combined with oral antibiotics
Trial: 32475458
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with 7.5 mg Cd/kg feed
Trial: 32475458
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with 15 mg Cd/kg feed
Trial: 32475458
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with 30 mg Cd/kg feed
Trial: 32475458
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with 60 mg Cd/kg feed
Trial: 35263688
Drug: Nutritional therapy
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional therapy
Trial: 32956651
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg daily
Trial: 32430334
Drug: Atezolizumab (anti-PD-L1)
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab (anti-PD-L1) monotherapy
Trial: 34881553
Drug: Caffeine (400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (400mg dose of caffeine anhydrous)
Trial: 38448895
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioral therapy (GCBT)
Trial: 33358119
Drug: Inhaled aztreonam
RxNorm normalized name: aztreonam Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled aztreonam lysine plus IV colistimethate (AZLI+IV)
Trial: 33358119
Drug: Dual IV
RxNorm normalized name: Dual IV Stand Adapter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual IV antibiotics (IV+IV)
Trial: 33436018
Drug: IBM score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBM score based on pre‐treatment contrast‐enhanced CT
Trial: 35996967
Drug: Emblica officinalis
RxNorm normalized name: Emblica officinalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emblica officinalis extract (EOE) 2 g
Trial: 35996967
Drug: Emblica officinalis
RxNorm normalized name: Emblica officinalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emblica officinalis extract (EOE) 1 g
Trial: 35100192
Drug: Titration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration of inspiratory support to obtain transdiaphragmatic pressure swings in the predefined 'diaphragm-protective' range (3-12 cm H2O)
Trial: 32611866
Drug: Clove-papaya based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clove-papaya based anesthetic gel
Trial: 36263451
Drug: Daily emollient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily emollient plus standard skin-care advice
Trial: 34015940
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg once daily for 6 months (n=642)
Trial: 32359142
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g PRO
Trial: 32359142
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g PRO
Trial: 32359142
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g PRO
Trial: 32359142
Drug: 45 g
RxNorm normalized name: SODIUM CHLORIDE 0.045 g in 5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 g PRO
Trial: 35303461
Drug: OptiMA strategy
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OptiMA strategy (a single programme for both severe acute malnutrition and moderate acute malnutrition using RUTF at a decreasing dose as MUAC and weight increased)
Trial: 35303461
Drug: Standard strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard strategy (one programme for severe acute malnutrition using ready‐to‐use therapeutic food [RUTF] at an increasing dose as weight increased, another for moderate acute malnutrition using a fixed dose of ready‐to‐use supplementary food [RUSF])
Trial: 35996891
Drug: Pilates-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilates-based exercise classes (four-week, twice-weekly)
Trial: 32319392
Drug: Low-dose bortezomib
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose bortezomib (0.7 mg/m2) + cyclophosphamide (0.5 g/m2) + dexamethasone
Trial: 32319392
Drug: Standard-dose bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard-dose bortezomib (1.3 mg/m2) + cyclophosphamide (0.5 g/m2) + dexamethasone
Trial: 32319392
Drug: Bortezomib (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (0.7 mg/m2) + dexamethasone
Trial: 32319392
Drug: Low-dose bortezomib-based
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose bortezomib-based therapy
Trial: 35875695
Drug: Dihydrocapsiate (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrocapsiate (12 mg)
Trial: 36152013
Drug: Non-cultured epidermal
RxNorm normalized name: omidubicel
DrugBank: Omidubicel (DB17132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-cultured epidermal cell suspension (ECS)
Trial: 36152013
Drug: Hair follicle
RxNorm normalized name: BIOTIN 2 g in 30 mL TOPICAL OIL [Reactivate Hair Follicles]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hair follicle cell suspension (HFCS)
Trial: 34236011
Drug: GB222 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB222 (1 mg/kg)
Trial: 34236011
Drug: Bevacizumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (1 mg/kg)
Trial: 33471112
Drug: Restarting golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Restarting golimumab treatment
Trial: 33471112
Drug: Step-down strategy
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step-down strategy to MTX monotherapy
Trial: 38824941
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard therapy
Trial: 35328990
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid and hyaluronic acid-based gel
Trial: 32100647
Drug: Multi-nutrient (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-nutrient (1 g DHA, 160 mg EPA, 240 mg Ginkgo biloba, 60 mg phosphatidylserine, 20 mg d‐α tocopherol, 1 mg folic acid and 20 g vitamin B12 per day)
Trial: 32100647
Drug: Multi-nutrient and
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-nutrient and exercise (spin class twice per week)
Trial: 34174970
Drug: Control (drug-free)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (drug-free)
Trial: 35985545
Drug: ETV+BRC and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETV+BRC and ETV monotherapy
Trial: 34732148
Drug: Multicomponent exercise
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent exercise intervention (60-min sessions, twice a week for 6 months)